Uneingeschränkter Zugang

Impact of the COVID-19 pandemic on young oncologists: The Greek perspective

Ioannis Ntanasis-Stathopoulos
Ioannis Ntanasis-Stathopoulos
, 
Charalampos Filippatos
Charalampos Filippatos
, 
Sofia Levva
Sofia Levva
, 
Konstantina Loga
Konstantina Loga
, 
Areti Kantzioura
Areti Kantzioura
 und 
Anastasios Kyriazoglou
Anastasios Kyriazoglou
   | 26. Apr. 2024
Forum of Clinical Oncology's Cover Image
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zitieren
Article Category: Research Article
Online veröffentlicht: 26. Apr. 2024
Seitenbereich: -
Eingereicht: 13. Dez. 2023
Akzeptiert: 22. Dez. 2023
DOI: https://doi.org/10.2478/fco-2023-0017
Schlüsselwörter
© 2024 Ioannis Ntanasis-Stathopoulos et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1:

Age distribution of the participants.
Age distribution of the participants.

Figure 2:

Average number of patients handled/treated per day.
Average number of patients handled/treated per day.

Figure 3:

New duties during the pandemic – as reported by the respondents.
New duties during the pandemic – as reported by the respondents.

Figure 3:

Impact of the pandemic on clinical and pre-clinical research output.
Impact of the pandemic on clinical and pre-clinical research output.

Figure 4:

Access to COVID-19 protective measures and equipment.
Access to COVID-19 protective measures and equipment.

Figure 5:

Fear of contracting or spreading COVID-19 during work.
Fear of contracting or spreading COVID-19 during work.

COVID-19 first-line safety and fear of spread.

Access to COVID-19 protective measures and equipment, n (%)
Optimal 14 (18.2%)
Sub-optimal 47 (61.0%)
Sufficient 13 (16.9%)
Insufficient 3 (3.9%)
Fear of being infected with SARS-CoV-2 or spreading it during work, n (%)
Constantly 42 (54.5%)
Sometimes 29 (37.7%)
Rarely 3 (3.9%)
Never 3 (3.9%)

Impact on research.

Time allocated on clinical research (clinical trials), n (%)
Increase 12 (15.6%)
Decrease 28 (36.4%)
Unchanged 37 (48.1%)
Time allocated on pre-clinical research, n (%)
Increase 10 (12.9%)
Decrease 32 (41.6%)
Unchanged 35 (45.5%)
COVID-19 related pre-clinical/clinical research, n (%)
Increase 16 (20.8%)
Decrease 13 (16.9%)
Unchanged 48 (62.3%)

Clinical experiences of the population.

Variables Measurements
Average patients per day, n (%)
1–5 5 (6.5%)
6–10 21 (27.3%)
11–15 18 (23.4%)
15–20 17 (22.1%)
20 16 (20.7%)
Everyday life at work at pro COVID-19 levels, n (%)
Yes 25 (32.5%)
No 52 (67.5%)
New duties during COVID-19? n (%)
Yes, COVID-19 clinic duties 18 (23.4%)
Yes, Partial change of duties 39 (50.6%)
No 20 (26.0%)
Duration of new duties, n (%)
<1 month 7 (9.0%)
1–3 months 16 (20.8%)
>3 months 32 (41.6%)
No new duties 22 (28.6%)
COVID-19 clinic duties, n (%)
Yes, <3 months 19 (24.6%)
Yes, >3 months 25 (32.5%)
No 33 (42.9%)
Remote patient consulting, n (%)
Increase 58 (75.3%)
Decrease 0 (0.0%)
Unchanged 19 (24.7%)
Remote (oncology) meetings, n (%)
Increase 61 (79.2%)
Decrease 3 (3.2%)
Unchanged 3 (16.9%)
Work from home, n (%)
Yes 28 (36.4%)
No 49 (63.6%)
Working hours, n (%)
Increase 57 (74.0%)
Decrease 2 (2.6%)
Unchanged 18 (23.4%)
Overtime working hours, n (%)
Increase 53 (68.8%)
Decrease 1 (1.3%)
Unchanged 23 (29.9%)
Overnight shifts, n (%)
Increase 40 (51.9%)
Decrease 0 (0.0%)
Unchanged 37 (48.1%)
Overnight shifts during holidays, n (%)
Increase 34 (44.2%)
Decrease 1 (1.3%)
Unchanged 42 (54.5%)

Participants’ perception of the effects of the pandemic on their personal lives and habits.

During the pandemic, I reassessed the value of work–life balance, n (%)
Strongly agree 25 (32.5%)
Agree 38 (49.4%)
Disagree 2 (2.6%)
Strongly disagree 1 (1.3%)
Uncertain 11 (14.2%)
Role of family during COVID-19, n (%)
Supportive and helped in reducing stress 22 (28.6%)
Elevated stress caused by concerns about the intra-family transmission of COVID-19 19 (24.7%)
I had to stay apart from my family for a period due to concerns about the transmission of SARS-CoV-2. 26 (33.8%)
Neutral impact during the pandemic 10 (12.9%)
Smoking during the pandemic, n (%)
Started 0 (0.0%)
Increased 6 (7.8%)
Decreased 8 (10.4%)
Stopped 2 (2.6%)
Non-smoker 61 (79.2%)
Alcohol during the pandemic, n (%)
Started 1 (1.3%)
Increased 14 (18.2%)
Decreased 10 (12.9%)
Stopped 3 (3.9%)
Non-drinker 49 (63.7%)
Psychotropic substances during the pandemic, n (%)
Started 1 (1.3%)
Increased 0 (0.0%)
Decreased 0 (0.0%)
Stopped 0 (0.0%)
Non-user 76 (98.7%)
Exercise during the pandemic, n (%)
Started 3 (3.9%)
Increased 14 (18.2%)
Decreased 40 (51.2%)
Stopped 7 (9.1%)
Does not exercise 13 (17.6%)
COVID-19 had a negative impact on sexual health, n (%)
Strongly agree 6 (7.8%)
Agree 21 (27.3%)
Disagree 23 (29.9%)
Strongly disagree 4 (5.1%)
Uncertain 23 (29.9%)
Sleep disorders during COVID-19, n (%)
Strongly agree 9 (11.7%)
Agree 23 (29.9%)
Disagree 23 (29.9%)
Strongly disagree 7 (9.1%)
Uncertain 15 (19.4%)

Participant's perceptions of the effects of the pandemic on their development.

COVID-19 will adversely affect my professional training, n (%)
Strongly agree 30 (38.9%)
Agree 32 (41.6%)
Disagree 4 (5.2%)
Strongly disagree 1 (1.3%)
Uncertain 10 (13%)
COVID-19 will adversely affect my career, n (%)
Strongly agree 13 (16.9%)
Agree 23 (29.9%)
Disagree 15 (19.4%)
Strongly disagree 3 (3.9%)
Uncertain 23 (29.9%)
COVID-19 has had a detrimental effect on potential opportunities for observerships/fellowships, n (%)
Strongly agree 38 (49.4%)
Agree 27 (35.1%)
Disagree 5 (6.5%)
Strongly disagree 0 (0.0%)
Uncertain 7 (9.0%)

Demographic characteristics of the population.

Variables Measurements
Age group, n (%)
21–30 33 (42.9%)
31–40 34 (44.2%)
41–50 9 (11.5%)
>50 1 (1.4%)
Sex, n (%)
Female 50 (64.9%)
Male 27 (35.1%)
Living alone, n (%)
Yes 37 (48%)
No 40 (52%)
Workplace location, n (%)
Athens or Thessaloniki 59 (76.6%)
Peloponnese 5 (6.5%)
Central Greece/Thessalia/Epirus 7 (9.1%)
Macedonia/Thrace 1 (1.3%)
Greek islands 1 (1.3%)
Living abroad 4 (5.2%)
Workplace type, n (%)
University Hospital 42 (54.5%)
General Public Hospital 15 (19.5%)
Anti-cancer Hospital 8 (10.4%)
Private Clinic 9 (11.7%)
Pharmaceutical company 1 (1.3%)
Laboratory 1 (1.3%)
Military Hospital 4 (5.2%)
Specialty, n (%)
Pathological Oncology 68 (88.3%)
Oncology–Hematology 3 (3.9%)
Research 1 (1.3%)
Pathology 3 (3.9%)
Nuclear medicine 1 (1.3%)
Rural service 1 (1.3%)
Specialty training, n (%)
Completed 28 (36.4%)
Undergoing 49 (63.6%)
Years undergoing training, n (%)
<2 14 (29.2%)
2–4 22 (45.8%)
5–6 12 (25%)
Years on practice post training, n (%)
<5 23 (82.1%)
5–10 3 (10.7%)
>10 2 (7.2%)
eISSN:
1792-362X
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
4 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Medizin, Klinische Medizin, Allgemeinmedizin, Innere Medizin, Hämatologie, Onkologie
Zeitschrift RSS Feed